Clinical trial
Effects of One Evening Dose of 3 mg Eszopiclone on Next Day Driving Ability
NCT00368056 · Sumitomo Pharma America, Inc., Industry · Completed
Key facts
| NCT number | NCT00368056 |
|---|---|
| Title | Effects of One Evening Dose of 3 mg Eszopiclone on Next Day Driving Ability |
| Official title | Effects of a Single Evening Dose of 3 mg Eszopiclone on Next Day Driving Ability and Psychomotor/Memory Function in Patients With Primary Insomnia Compared to Placebo |
| Lead sponsor | Sumitomo Pharma America, Inc., Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Primary Insomnia |
| Intervention type | Drug |
| Interventions | Eszopiclone, Placebo |
| Enrollment | 32 |
| Start date | Apr 1, 2005 |
| Primary completion | Jun 1, 2006 |
| Completion | Jun 1, 2006 |
| First posted | Aug 24, 2006 |
| Last update posted | Feb 22, 2012 |
| Countries | United Kingdom |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: